| Ticker |
SRPT
|
| CIK | 0000873303 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142 |
| Website | sarepta.com |
| Phone | 617-274-4000 |
| CEO | Douglas S. Ingram |
| Employees | 840 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
493 employees laid off at biopharmaceutical company with operations in AndoverANDOVER — A biopharmaceutical research company with ties in Andover has laid off a third of its workforce as one of the industry leaders in gene therapy goes through a “strategic restructuring.” Sarepta Therapeutics engineers precision genetic medicine for rare diseases such as Duchenne muscular dystrophy, limb-girdle muscular dystrophies and charcot-marie-tooth disease. Its pipeline has 40 ... George Tidmarsh to sub in as FDA CBER head following Prasad’s shock exitTidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead. Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough DealWe recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs. Its proprietary TRiM platform enables precise silencing of disease-causing genes, positioning the company […] Will Insmed (INSM) Report Negative Earnings Next Week? What You Should KnowInsmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Sarepta Therapeutics to Announce Second Quarter 2025 Financial ResultsCAMBRIDGE, Mass., July 31, 2025--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nasdaq Global Market closes on Wednesday, August 6, 2025. As announced on July 16, 2025, the Company will not be hosting a conference call to discuss results at this time. |
